Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children

AIDS Research and Human Retroviruses

Volumn 29, Issue 3, 2013, Pages 449-455

  Musiime, Victor ^a   Kaudha, Elizabeth ^a   Kayiwa, Joshua ^a   Mirembe, Grace ^a   Odera, Matthew ^a   Kizito, Hilda ^a   Nankya, Immaculate ^a   Ssali, Francis ^a   Kityo, Cissy ^a   Colebunders, Robert ^b   Mugyenyi, Peter ^a  

^a JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CD4 ANTIGEN; EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THYMIDINE DERIVATIVE; ZIDOVUDINE;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; BODY HEIGHT; BODY WEIGHT; CHILD; COHORT ANALYSIS; DRUG TREATMENT FAILURE; FEMALE; GENE INSERTION; GENE MUTATION; GENETIC RESISTANCE; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION; TREATMENT RESPONSE; UGANDA; VIRUS LOAD;

ADOLESCENT; ANTI-RETROVIRAL AGENTS; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION, MISSENSE; TREATMENT OUTCOME; UGANDA; VIRAL LOAD; VIRAL PROTEINS; YOUNG ADULT;

EID: 84874475188     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0283     Document Type: Article

References (34)

1. UNAIDS: Global report: UNAIDS report on the global AIDS epidemic, 2010.
2. WHO: Uganda leads the way in innovative AIDS treatment. www.who.int/bulletin/volumes/83/4/infocus 0405/en. Accessed December 15, 2005.
3. MOH-Uganda: ART scale up - where we stand: Lessons learned and challenges. In: 3rd National HIV update meeting, Kampala, Uganda, 7-9 September 2011.
4. Hamers RL, Wallis CL, Kityo C, et al.: HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: A multicentre observational study. Lancet Infect Dis 2011;11(10):750-759.
5. Ndembi N, Hamers RL, Sigaloff KC, et al.: Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala. AIDS 2011;25(7):905-910.
6. Barth RE, Tempelman HA, Smelt E, Wensing AM, Hoepelman AI, and Geelen SP: Long-term outcome of children receiving antiretroviral treatment in rural South Africa: Substantial virologic failure on first-line treatment. Pediatr Infect Dis J 2011;30(1):52-56.
7. Charpentier C, Gody JC, Mbitikon O, et al.: Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A crosssectional evaluation in HIV Type 1-infected children living in the Central African Republic. AIDS Res Hum Retroviruses 2012;28(1):87-94.
8. Gupta RK, Ford D, Mulenga V, et al.: Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine. Pediatr Infect Dis J 2010;29(8):e57-62.
9. Musiime V, Ssali F, Kayiwa J, et al.: Response to nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-infected children with perinatal exposure to single-dose nevirapine. AIDS Res Hum Retroviruses 2009;25:989-996.
10. Ruel TD, Kamya MR, Li P, et al.: Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children. J Acquir Immune Defic Syndr 2011;56:44-50.
11. Sigaloff KC, Calis JC, Geelen SP, van Vugt M, and de Wit TF: HIV-1-resistance-Associated mutations after failure of firstline antiretroviral treatment among children in resourcepoor regions: A systematic review. Lancet Infect Dis 2011; 11(10):769-779.
12. Zhang F, Haberer J, Wei H, et al.: Drug resistance in the Chinese National Pediatric Highly Active Antiretroviral Therapy Cohort: Implications for paediatric treatment in the developing world. Int J STD AIDS 2009;20:406-409.
13. WHO: Antiretroviral therapy for HIV infection in infants and children: Towards universal access; recommendations for a public health approach - 2010 revision. WHO, Geneva, Switzerland, 2010.
14. Stanford University: HIV Drug resistance database. In. hivdb.stanford.edu. Accessed September 30, 2011.
15. Johnson VA, Calvez V, Gunthard HF, Paredes R, et al.: 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011;19(4):156-164.
16. Bratholm C, Johannessen A, Naman E, et al.: Drug resistance is widespread among children who receive long-term antiretroviral treatment at a rural Tanzanian hospital. J Antimicrob Chemother 2010;65:1996-2000.
17. Figueiredo Saad F, Kaminami Morimoto H, Wiechmann SL, Bonametti AM, et al.: Frequency and diversity of human immunodeficiency virus type 1 mutations associated with antiretroviral resistance among patients from Southern Brazil failing highly active antiretroviral therapy (HAART). Int J Mol Med 2010;26(4):585-593.
18. Mohamad S, Deris ZZ, Yusoff NK, Ariffin TA, and Shueb RH: Assessing subtypes and drug resistance mutations among HIV-1 infected children who failed antiretroviral therapy in Kelantan, Malaysia. Braz J Infect Dis 2012;16(3):284-288.
19. Puthanakit T, Jourdain G, Hongsiriwon S, et al.: HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. HIV Med 2010;11:565-557.
20. AIDS-Info: FDA-Approved Anti-HIV Medications. In: www.aidsinfo.nih.gov/ contentfiles/ApprovedMedstoTreat HIV-FS-en.pdf. Accessed August 24, 2012.
21. Hawkins CA, Chaplin B, Idoko J, Ekong E, et al.: Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. J Acquir Immune Defic Syndr 2009;52(2):228-234.
22. Wallis CL, Mellors JW, Venter WDF, Sanne I, and Stevens W: Varied patterns of HIV-1 drug resistance on failing firstline antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010;53(4):480-484.
23. Harrigan PR, Stone C, Griffin P, Najera I, et al.: Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. J Infect Dis 2000;181(3):912-920.
24. Kuritzkes DR: Clinical significance of drug resistance in HIV-1 infection. AIDS 1996;10(Suppl 5):527-531.
25. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, and Maartens G: Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 2007;146:564-573.
26. Nachega JB, Hislop M, Nguyen H, et al.: Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr 2009;51:65-71.
27. Nolan S, Milloy MJ, Zhang R, et al.: Adherence and plasma HIV RNA response to antiretroviral therapy among HIVseropositive injection drug users in a Canadian setting. AIDS Care 2011;23:980-987.
28. Bannister WP, Ruiz L, Cozzi-Lepri A, et al.: Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. AIDS 2008;22:367-376.
29. Manfredi R, Calza L, and Chiodo F: Efavirenz versus nevirapine in current clinical practice: A prospective, openlabel observational study. J Acquir Immune Defic Syndr 2004;35:492-502.
30. Lapphra K, Vanprapar N, Chearskul S, et al.: Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children. Int J Infect Dis 2008; 12:e33-38.
31. Manosuthi W, Sungkanuparph S, Vibhagool A, Rattanasiri S, and Thakkinstian A: Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naive patients with advanced HIV infection. HIV Med 2004;5:105-109.
32. Patel AK, Pujari S, Patel K, et al.: Nevirapine versus efavirenz based antiretroviral treatment in naive Indian patients: Comparison of effectiveness in clinical cohort. J Assoc Physicians India 2006;54:915-918.
33. Marape M: Regimen-specific adherence to antiretroviral therapy among HIV-infected adolescents at a paediatric HIV treatment centre in Gaborone, Botswana. In: 4th International Workshop on HIV Pediatrics, Washington, DC, 2012.
34. Zhao Y, Mu W, Harwell J, et al.: Drug resistance profiles among HIV-1-infected children experiencing delayed switch and 12-month efficacy after using second-line antiretroviral therapy: An observational cohort study in rural China. J Acquir Immune Defic Syndr 2011;58:47-53.